Evonik has announced a €25 million ($27m) first stage of a long-term programme to expand the capacity of its Dossenheim and Hanau facilities in Germany to support growing pharmaceutical demand for the contract manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates within Europe.
The $27m first stage of the expansion project for Dossenheim and Hanau is scheduled to be completed by the middle of 2021, with the entire project expected to be finalised prior to 2024.
"The COVID-19 pandemic has amplified the focus of many pharmaceutical companies to have European-based manufacturing sites that can support the production of their life-saving drug products for reliable supply to regional healthcare markets," said Thomas Riermeier, Senior VP of Evonik's Health Care business line. "The expansion of our Dossenheim and Hanau sites in Germany is now underway to support customers seeking a trusted European site for the clinical and commercial production of their APIs and intermediates."
"In addition to increasing our production capacity for APIs and advanced intermediates within Europe, the expansion of the two multi-purpose cGMP sites in Dossenheim and Hanau, Germany will widen Evoni's ability to support highly complex customer projects", said Dr Andreas Meudt, VP of Exclusive Synthesis for the Health Care business line of Evonik.
Such complex API projects, which are often associated with oncological, anti-viral and other specialised drug products, typically require a range of advanced technologies including continuous processing, highly pure PEGs and mPEGs, catalysis and cryogenic chemistry.
Evonik is one a CMO for APIs and intermediates, and a large manufacturer of high potency APIs (HPAPIs). It has established a broad portfolio of advanced technologies across its network of CMO sites in the US, Germany, France, Slovakia and China.
